# Barbara Buldini

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 64 papers | 2,481 citations | 236612 25 h-index | 205818 48 g-index |
| 64 all docs | 64 docs citations | 64 times ranked | 3700 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | SF3B1 homeostasis is critical for survival and therapeutic response in T cell leukemia. Science Advances, 2022, 8, eabj8357. | 4.7 | 16 |
| 2 | NUP214â€“ABL1 fusion in childhood Tâ€ALL. Pediatric Blood and Cancer, 2022, 69, e29643. | 0.8 | 4 |
| 3 | mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells. Redox Biology, 2022, 51, 102268. | 3.9 | 14 |
| 4 | FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD). Cancers, 2022, 14, 2475. | 1.7 | 3 |
| 5 | Childhood cancer in Italy: background, goals, and achievements of the Italian Paediatric Hematology Oncology Association (AIEOP). Tumori, 2021, 107, 370-375. | 0.6 | 11 |
| 6 | <scp>CD56</scp>, <scp>HLAâ€DR,</scp> and <scp>CD45</scp> recognize a subtype of childhood <scp>AML</scp> harboring <scp>CBFA2T3â€GLIS2</scp> fusion transcript. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 844-850. | 1.1 | 10 |
| 7 | Targeting mesenchymal stromal cells plasticity to reroute acute myeloid leukemia course. Blood, 2021, 138, 557-570. | 0.6 | 26 |
| 8 | Prognostic Role of Minimal Disseminated Disease and NOTCH1/FBXW7 Mutational Status in Children with Lymphoblastic Lymphoma: The AIEOP Experience. Diagnostics, 2021, 11, 1594. | 1.3 | 4 |
| 9 | An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers, 2021, 13, 6148. | 1.7 | 24 |
| 10 | Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols. Haematologica, 2020, 105, 1887-1894. | 1.7 | 33 |
| 11 | Nextâ€generation sequencing of PTEN mutations for monitoring minimal residual disease in Tâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28025. | 0.8 | 3 |
| 12 | The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064. | 2.5 | 5 |
| 13 | Prognostic value of minimal residual disease measured by flow-cytometry in two cohorts of infants with acute lymphoblastic leukemia treated according to either MLL-Baby or Interfant protocols. Leukemia, 2020, 34, 3042-3046. | 3.3 | 13 |
| 14 | Health technology assessmentâ€“based approach to flow cytometric immunophenotyping of acute leukemias: a literature classification. Tumori, 2020, 106, 249-256. | 0.6 | 0 |
| 15 | Minimal residual disease analysis in childhood mature Bâ€cell leukaemia/lymphoma treated with AIEOP LNHâ€97 protocol with/without antiâ€CD20 administration. British Journal of Haematology, 2020, 189, e108-e111. | 1.2 | 8 |
| 16 | Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. European Journal of Cancer, 2020, 132, 11-16. | 1.3 | 155 |
| 17 | Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. Blood, 2020, 136, 26-27. | 0.6 | 1 |
| 18 | Hematopoietic stem cell transplantation for isolated extramedullary relapse of acute lymphoblastic leukemia in children. Bone Marrow Transplantation, 2019, 54, 275-283. | 1.3 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. Frontiers in Pediatrics, 2019, 7, 412. | 0.9 | 27 |
| 20 | CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica, 2019, 104, e352-e355. | 1.7 | 42 |
| 21 | Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2019, 60, 2825-2828. | 0.6 | 8 |
| 22 | Flowâ€cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric Bâ€cell precursor acute lymphoblastic leukemia in trial AIEOPâ€BFMâ€ALL 2000. Pediatric Blood and Cancer, 2019, 66, e27590. | 0.8 | 18 |
| 23 | Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML. Leukemia, 2018, 32, 1124-1134. | 3.3 | 17 |
| 24 | Preâ€and postâ€transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2018, 180, 680-693. | 1.2 | 44 |
| 25 | International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood, 2018, 132, 264-276. | 0.6 | 70 |
| 26 | <scp>AIEOP</scp>â€<scp>BFM</scp> Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2018, 94, 82-93. | 0.7 | 96 |
| 27 | DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol. Pharmacogenomics, 2018, 19, 105-112. | 0.6 | 11 |
| 28 | Unrelated donor vs HLA-haploidentical Î±/Î² T-cellâ€“ and B-cellâ€“depleted HSCT in children with acute leukemia. Blood, 2018, 132, 2594-2607. | 0.6 | 101 |
| 29 | A Novel t(8;14)(q24;q11) Rearranged Human Cell Line as a Model for Mechanistic and Drug Discovery Studies of NOTCH1-Independent Human T-Cell Leukemia. Cells, 2018, 7, 160. | 1.8 | 9 |
| 30 | The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379. | 13.7 | 236 |
| 31 | Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing. Pharmacogenomics, 2018, 19, 1181-1193. | 0.6 | 27 |
| 32 | The presence of mutated and deleted <scp>PTEN</scp> is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with <scp>AIEOP</scp>â€<scp>BFM ALL</scp> protocols. British Journal of Haematology, 2018, 182, 705-711. | 1.2 | 30 |
| 33 | Characterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Leukemia, 2017, 31, 18-25. | 3.3 | 29 |
| 34 | Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL. Leukemia, 2017, 31, 1007-1011. | 3.3 | 27 |
| 35 | Prognostic significance of flowâ€cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the <scp>AIEOP</scp>â€<scp>AML</scp> 2002/01 study protocol. British Journal of Haematology, 2017, 177, 116-126. | 1.2 | 54 |
| 36 | A Case of Tâ€cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia. Pediatric Blood and Cancer, 2016, 63, 1660-1663. | 0.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Expression of the immunoglobulin superfamily cell membrane adhesion molecule Cd146 in acute leukemia. Cytometry Part B - Clinical Cytometry, 2016, 90, 247-256. | 0.7 | 5 |
| 38 | Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematology,the, 2016, 3, e80-e86. | 2.2 | 95 |
| 39 | CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. Oncotarget, 2016, 7, 59260-59272. | 0.8 | 24 |
| 40 | Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e229-e232. | 1.7 | 29 |
| 41 | Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience. Pediatric Blood and Cancer, 2015, 62, 1906-1913. | 0.8 | 32 |
| 42 | Leukemia blast cell identification. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery, 2015, 5, 74-85. | 4.6 | 0 |
| 43 | Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement. Haematologica, 2015, 100, e99-e101. | 1.7 | 35 |
| 44 | Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica, 2015, 100, 935-944. | 1.7 | 64 |
| 45 | Flow diagnostics essential code: A simple and brief format for the summary of leukemia phenotyping. , 2014, 86, 288-291. | | 10 |
| 46 | Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study. Blood, 2014, 124, 3780-3780. | 0.6 | 1 |
| 47 | Low PKCÎ± expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget, 2014, 5, 5234-5245. | 0.8 | 20 |
| 48 | Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia. Leukemia, 2013, 27, 2419-2421. | 3.3 | 25 |
| 49 | Flow diagnostics essential (FDE) code: A simple and brief format for the summary of leukemia phenotyping. , 2013, , n/a-n/a. | | 5 |
| 50 | Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica, 2012, 97, 1582-1593. | 1.7 | 95 |
| 51 | Trisomy 7 and Deletion of the 9p21 Locus As Novel Acquired Abnormalities in a Case Of Pediatric Biphenotypic Acute Leukemia. Journal of Pediatric Hematology/Oncology, 2012, 34, e126-e129. | 0.3 | 2 |
| 52 | Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 2011, 118, 2077-2084. | 0.6 | 370 |
| 53 | MLL partner genes drive distinct gene expression profiles and genomic alterations in pediatric acute myeloid leukemia: an AIEOP study. Leukemia, 2011, 25, 560-563. | 3.3 | 31 |
| 54 | Identification of immunophenotypic signatures by clustering analysis in pediatric patients with Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. American Journal of Hematology, 2010, 85, 138-141. | 2.0 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. Journal of Clinical Oncology, 2009, 27, 5168-5174. | 0.8 | 247 |
| 56 | Advanced pediatric myelodysplastic syndromes: Can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?. Pediatric Blood and Cancer, 2009, 52, 357-363. | 0.8 | 30 |
| 57 | Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group. Blood, 2008, 112, 700-700. | 0.6 | 3 |
| 58 | Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infectious Diseases, 2007, 7, 28. | 1.3 | 60 |
| 59 | Immunophenotype signature as a tool to define prognostic subgroups in childhood acute myeloid leukemia. Leukemia, 2006, 20, 888-891. | 3.3 | 5 |
| 60 | Spinal cord injury without radiographic abnormalities. European Journal of Pediatrics, 2006, 165, 108-111. | 1.3 | 35 |
| 61 | Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. Experimental Hematology, 2006, 34, 934-942. | 0.2 | 42 |
| 62 | Symmetrical thalamic calcifications in a monozygotic twin: case report and literature review. Brain and Development, 2005, 27, 66-69. | 0.6 | 7 |
| 63 | Acute Lymphoid Leukaemias (ALL) and Minimal Residual Disease in ALL. , 0, , 89-104. | | 1 |
| 64 | Phosphoproteomic Analysis Reveals a Different Proteomic Profile in Pediatric Patients With T-Cell Lymphoblastic Lymphoma or T-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology, 0, 12, . | 1.3 | 2 |